Results 111 to 120 of about 412,436 (221)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

open access: yes, 2016
Kris Vaddi,1 Srdan Verstovsek,2 Jean-Jacques Kiladjian3 1Drug Discovery, Incyte Corporation, Wilmington, DE, 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Clinical Investigations Center, Hôpital ...
Kiladjian JJ, Vaddi K, Verstovsek S
core  

Autoimmunity and peginterferon therapy for polycythemia vera. [PDF]

open access: yesHemasphere
Rivière E   +8 more
europepmc   +1 more source

Correction to: Modern and multidisciplinary care in polycythemia vera. [PDF]

open access: yesAnn Hematol
Palandri F   +20 more
europepmc   +1 more source

Modern and multidisciplinary care in polycythemia vera. [PDF]

open access: yesAnn Hematol
Palandri F   +20 more
europepmc   +1 more source

Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis. [PDF]

open access: yesMedicine (Baltimore)
Bakht D   +12 more
europepmc   +1 more source

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib. [PDF]

open access: yesBlood Adv
Palandri F   +26 more
europepmc   +1 more source

Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera. [PDF]

open access: yesAnn Med
Hantrakun N   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy